+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic significance of serum c-erbB-2 protein in breast cancer patients



Prognostic significance of serum c-erbB-2 protein in breast cancer patients



Breast Cancer Research & Treatment 40(3): 251-255



The tissue expression of c-erbB-2 protein in breast cancer is a marker of poor prognosis in a number of studies. More recently it has also been suggested that c-erbB-2 expression may predict response to systemic therapy in patients with advanced breast cancer. The measurement of c-erbB-2 protein in the serum of breast cancer patients has now been reported, but the significance of this finding is not clear. In this study an ELISA assay was used to measure c-erbB-2 in the sera of 23 normal controls, 46 benign breast disease patients, and 119 breast cancer patients. Elevated serum c-erbB-2 protein levels were detected in 13% (3/23) of normal controls, 15% (7/46) of benign disease patients, 15% (7/46) of Stage I/II patients, 26% (9/35) of Stage III patients, and 21% (8/38) of Stage IV patients. The tissue expression of the c-erbB-2 protein showed no association with detection of the serum c-erbB-2 protein (p = 0.31). In the 67 Stage III and IV patients who had assessable disease the presence of the c-erbB-2 protein in the serum bore no relationship to response to hormonal therapy (p = 0.71). Serum detection of the c-erbB-2 protein in Stage I/II patients predicted for a worsening of both survival outcome (p = 0.002) and disease free interval (p = 0.002). A worse outcome was also seen for the Stage III patients (p = 0.04) and Stage IV patients, although the latter did not reach statistical significance (p = 0.27). This study found that the presence of c-erbB-2 in the serum of breast cancer patients was of prognostic significance for all stages of disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009254685

Download citation: RISBibTeXText

PMID: 8883967

DOI: 10.1007/bf01806813


Related references

Prognostic significance of overexpression of serum c-erbB-2 protein in primary breast cancer patients. Breast 10(Supplement 1): S20, 2001

Prognostic significance of overexpression of cytosol and serum c-erbB-2 protein in primary breast cancer patients. Breast Cancer Research & Treatment 57(1): 101, 1999

The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer. Oncology 55(1): 33-38, 1998

The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 55(1): 33-38, 1998

Prognostic significance of serum C-erbB-2 levels in hormonally treated advanced breast cancer patients. Anticancer Research 19(6D): 5693-5694, 1999

Serum c-erbB-2 protein is an independent prognostic factor in operable breast cancer patients. Clinical Chemistry 48(6 Supplement): A14, 2002

Clinical significance of serum c-erbB-2 protein in patients with primary breast cancer. Oncology Reports 4(2): 349-352, 1997

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology 8(1): 103-112, 1990

Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(7): 1181-1185, 1991

Prognostic significance of circulating C-ErbB-2 in locally advanced breast cancer patients. Tumor Biology 18(SUPPL 1): 97, 1997

Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Research 17(1b): 757-760, 1997

Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. Journal of Clinical Oncology 16(7): 2409-2416, 1998

Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. American Journal of Surgery 164(4): 323-326, 1992

c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patients. Breast 11(4): 286-294, 2004

Serum c-erbB-2 protein in breast cancer patients. Journal of the Medical Association of Thailand 83(8): 886-893, 2000